Seamus Fernandez
Stock Analyst at Guggenheim
(4.39)
# 361
Out of 4,970 analysts
107
Total ratings
52.7%
Success rate
19.96%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TENX Tenax Therapeutics | Maintains: Buy | $15 → $14 | $5.96 | +134.90% | 2 | Aug 14, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $942 → $875 | $730.26 | +19.82% | 18 | Aug 13, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $92 → $90 | $20.47 | +339.67% | 2 | Aug 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $119 → $120 | $103.12 | +16.37% | 2 | Aug 6, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | $116 | $37.21 | +211.74% | 8 | Jul 2, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Buy | $50 → $68 | $64.45 | +5.51% | 4 | Jun 24, 2025 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $17 | $9.99 | +70.17% | 1 | Jun 24, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $12.35 | +256.28% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $16.60 | - | 3 | Apr 3, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $33.01 | +384.70% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $56 | $35.06 | +59.75% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $33.22 | - | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $122 | $84.44 | +44.48% | 14 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $40.09 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.10 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.65 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $18.45 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.83 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $55.42 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $130.41 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.98 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $2.12 | +2,453.19% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $23.31 | +93.09% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $81.82 | -53.56% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $24.70 | +53.85% | 3 | Jan 31, 2018 |
Tenax Therapeutics
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $5.96
Upside: +134.90%
Eli Lilly and Company
Aug 13, 2025
Maintains: Buy
Price Target: $942 → $875
Current: $730.26
Upside: +19.82%
Structure Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $92 → $90
Current: $20.47
Upside: +339.67%
Rhythm Pharmaceuticals
Aug 6, 2025
Maintains: Buy
Price Target: $119 → $120
Current: $103.12
Upside: +16.37%
Apogee Therapeutics
Jul 2, 2025
Reiterates: Buy
Price Target: $116
Current: $37.21
Upside: +211.74%
Cidara Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $50 → $68
Current: $64.45
Upside: +5.51%
Amylyx Pharmaceuticals
Jun 24, 2025
Initiates: Buy
Price Target: $17
Current: $9.99
Upside: +70.17%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $12.35
Upside: +256.28%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $16.60
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $33.01
Upside: +384.70%
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $35.06
Upside: +59.75%
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $33.22
Upside: -
Jan 17, 2025
Maintains: Buy
Price Target: $130 → $122
Current: $84.44
Upside: +44.48%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $40.09
Upside: -
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.10
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $18.45
Upside: -
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $46.83
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $55.42
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $130.41
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.98
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $2.12
Upside: +2,453.19%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $23.31
Upside: +93.09%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $81.82
Upside: -53.56%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $24.70
Upside: +53.85%